Traditional Culture Encyclopedia - Photography and portraiture - Ovariectomy-free hormone and chemotherapy rescue for prostate cancer

Ovariectomy-free hormone and chemotherapy rescue for prostate cancer

Men suffering from prostate cancer in Taiwan Province Province have a younger trend! According to the cancer registration statistics of the Department of Health in 1998, male-specific prostate cancer is the sixth largest cancer in China. Compared with 1997, the number of cancer patients increased by 4 10, even exceeding the growth rate of female cervical cancer. Doctors recommend that men over the age of 50 have finger examination and serum PSA examination every year. When anal examination reveals suspicious mass or PSA is higher than 4.0ng/ml, further transrectal prostate biopsy should be performed to find early treatment.

Male prostate cancer is the sixth largest cancer in China. 1998 cancer patients increased by 4 10 compared with 1997, and the growth rate even exceeded that of female cervical cancer. Zhangyan Hua, chief urologist of Beirong, said that more and more young patients are suffering from prostate cancer, and they often face the dilemma of saving their lives or not saving their testicles. In the clinic, a 38-year-old man went to see a doctor because of hemorrhoids, and found that there was something wrong with his prostate. It was found that the PSA value of prostate cancer index exceeded 85, and the emergency operation was advanced prostate cancer. Fortunately, hormone therapy and chemotherapy were effective, and the traditional castration method was cancelled, and he still maintained normal * * * and erectile function.

The early symptoms of prostate cancer are not obvious and the incubation period is long, which mainly occurs in men aged 65 ~ 85. Many people think that prostate cancer is a disease of the elderly, but it is not. With the recent westernization of diet, eating too elaborate or processed with too many additives, there are more and more middle-aged and elderly people in their 40 s, and patients tend to be younger.

Dr. zhangyan Hua said that because of the lack of health education information about prostate cancer in Taiwan Province Province, most patients were at an advanced stage when they went to see a doctor. Therefore, both the American Urology Medical Association and the American Cancer Medical Association recommend that men over 50 years old should have a * * * finger examination and serum PSA examination every year. When suspicious mass is found in anal examination or PSA is higher than 4.0ng/ml, transrectal prostate biopsy should be further performed for early detection and treatment.

Doctor zhangyan Hua said that more and more young patients with prostate cancer in China often face the dilemma of saving lives or losing testicles. (Photo/Zhang Shijie) In addition, in the past, the treatment of advanced prostate cancer was mainly testicular resection and oral androgen preparation to achieve the effect of inhibiting androgen "castration". Although there are two epididymis in the scrotum, the empty appearance has lost its normal sexual function, which has caused great negative psychological pressure to many people who have cancer at a young age and need sex.

Dr. zhangyan Hua emphasized that for young patients with prostate cancer, it is not necessary to remove "testicles". At present, the androgen receptor can be inhibited by drugs, and the androgen concentration in the blood of patients with prostate cancer can still remain normal, and * * * can erect. Take this 38-year-old man as an example. So far, he has been fighting cancer for 12 years, and his sex life is still happy.

However, after hormone therapy, most patients with prostate cancer will develop drug resistance, and the tumor will metastasize to pelvic lymph nodes and whole body bones, causing severe pain and fractures and other side effects. At this time, chemotherapy must be used to alleviate the pain and maintain the quality of life. At present, there is also a new generation of chemotherapy drug cabetaxel, which can reduce the mortality rate by 30% after the failure and metastasis of hormone therapy. It is a new choice for men with prostate cancer.